In line with the complex genetic structure of MM, most of the mutations were detected only in single patient samples (e.g., NRAS, ATM, NTRK1, cMET, HER2, BRAF, IDH1, IDH2) (see Figure 1), and most of them were not targetable in MM and other cancers beyond clinical trials. This evidence concerns the gene IDH2 and Miyoshi myopathy.